PapersPMID:31740020
Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone.
- 01 · findings
- 2
- 02 · compound
- 1
- 03 · endpoints
- 2
- 04 · null
- 2
all-cis-5,8,11,14,17-icosapentaenoic acid- Population, every finding
- Meta-analysis with trial sequential analysis of 5 RCTs (n=27,415) of EPA + statin vs statin alone; statin given as background therapy in both arms.
Every finding here is a null result.
What did not
2 findingsHow to read these marks →all-cis-5,8,11,14,17-icosapentaenoic acid — no detected effect on incidence of stroke
very limitedFindingNull result
“However, combined therapy of EPA + statin demonstrated no significant association on incidence of stroke when compared with statin alone or all-cause mortality.”
Quoted verbatim from Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone. - Study
- meta-analysis
all-cis-5,8,11,14,17-icosapentaenoic acid — no detected effect on all-cause mortality
very limitedFindingNull result
“However, combined therapy of EPA + statin demonstrated no significant association on incidence of stroke when compared with statin alone or all-cause mortality.”
Quoted verbatim from Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone. - Study
- meta-analysis
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Patients in 5 RCTs comparing EPA + statin versus statin alone, cardiovascular outcomes
- Participants
- 27,415
- Comparator
- an active treatment
- Duration
- not recorded
- Endpoints measured
- 5
- Record
- declined
- Declined
- another reason, stated per paper
- Readings recorded
- 1